Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This post-marketing observational study is conducted for obtaining data on clinical, biological and virological outcomes, compliance and tolerability of using a lopinavir/ritonavir (LPV/r) -containing regimen for the treatment of naïve or experienced patients infected with human immunodeficiency virus type 1 (HIV-1) in China.

Although LPV/r is frequently used world-wide, the evaluation of the outcomes, compliance, and tolerance of anti-HIV strategies in real life is still a major challenge in the management of HIV-infected patients who are on a life-long therapy, especially in China.

This study will help to develop effectiveness and safety profile of the lopinavir/ritonavir containing regimen in Chinese HIV-1 infected patients, provide more choices of anti-HIV-1 strategies to Chinese experts and benefits Chinese HIV-1 infected patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• Patients infected by HIV-1 who are over 18 years old

• Patients who belong to one of the following cohorts:

• Antiretroviral naïve patients

• Antiretroviral experienced patients, irrespective to their immune and viral status and current antiretroviral therapy

Exclusion Criteria:

• Patients who have been treated with lopinavir/ritonavir

• Patients who are being treated or will be treated with drugs at risk of interactions with lopinavir/ritonavir

• Patients who are not tolerant to lopinavir/ritonavir

• Patients who have uncontrolled AIDS defining disease

• Patients participating in another clinical trial